Israel Englander’s Celldex Therapeutics CLDX Stock Holding History

Israel Englander’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,000	Closed	-$1.02M	–	6010
2024 Q3	$1.02M	Buy	+30,000	New	+$1.14M	﹤0.01%	4263
2023 Q1	–	Sell	-20,000	Closed	-$891K	–	6426
2022 Q4	$891K	Buy	+20,000	New	+$714K	﹤0.01%	4276
2020 Q3	–	Sell	-31,200	Closed	-$406K	–	4482
2020 Q2	$406K	Buy	+31,200	New	+$138K	﹤0.01%	3527
2018 Q2	–	Sell	-16,667	Closed	-$583K	–	3819
2018 Q1	$583K	Buy	+16,667	New	+$646K	﹤0.01%	2957
2014 Q2	–	Sell	-5,460	Closed	-$1.45M	–	3443
2014 Q1	$1.45M	Sell	5,460 -953	-15%	-$365K	﹤0.01%	2004
2013 Q4	$2.33M	Buy	+6,413	New	+$2.47M	0.01%	1720

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's CLDX Position: Q2 2026 in Review

Israel Englander reduced its Celldex Therapeutics (CLDX) stake by 6.6% in Q2 2026, selling an estimated $2.67M and leaving 1,170,787 shares worth $43.6M. The position accounts for 0.02% of the portfolio, ranked #984.

Israel Englander first reported a position in CLDX in Q2 2013 and has held it in 42 quarters since. The position peaked at $57.7M in Q1 2015. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Israel Englander held 1,170,787 shares of Celldex Therapeutics worth $43.6M as of Q2 2026.
Israel Englander sold 82,745 Celldex Therapeutics shares in Q2 2026, an estimated $2.67M.
Celldex Therapeutics made up 0.02% of Israel Englander's portfolio in Q2 2026, its #984 holding.
Israel Englander first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 42 quarters since.
Israel Englander's Celldex Therapeutics position peaked at $57.7M in Q1 2015.
252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.